Asia One1d
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...
manilatimes1h
BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®
BrightSpring Health Services ("BrightSpring” or "BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a ...
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...
BrainTransporter™ dramatically improves antibody delivery to the brain
BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the ...
pharmaphorum1d
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...
Morningstar6d
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ --BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License ...
pharmaphorum11h
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal casts long shadow
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
The Pharma Letter5d
BRIEF—Eisai completes rolling submission to US FDA for Leqembi maintenance dosing
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) ...